Determination of A 3,4-diaminopyridine in plasma by liquid chromatography with electrochemical detection using solid-phase extraction

被引:6
作者
Goulay-Dufaÿ, S [1 ]
Do, B [1 ]
Le Hoang, MD [1 ]
Raust, JA [1 ]
Graffard, H [1 ]
Guyon, F [1 ]
Pradeau, D [1 ]
机构
[1] AGEPS, Analyt Dev Dept, F-75005 Paris, France
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2004年 / 805卷 / 02期
关键词
3,4-diaminopyridine;
D O I
10.1016/j.jchromb.2004.03.010
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
In order to quantify a small amount of a drug, 3,4-diaminopyridine (3,4-DAP), in animal plasma samples, an analytical method was developed. It involved an extraction of 3,4-DAP and phenylephrine, used as internal standard (IS), from plasma with solid-phase extraction (SPE) on C18 cartridges. This analytical method is a hyphenated technique based on high-performance liquid chromatography with electrochemical detection (HPLC-EC) whose purpose is to obtain first a sensitive method and second a satisfying separation between 3,4-DAP and phenylephrine. The analytical method is accurate, specific, and linear between 10 and 500 mug of 3,4-DAP per litre. The recovery of 3,4-DAP is estimated at 70.8% with a 95% confidence interval of (66.0-75.6%). Intermediate precision was evaluated on three quality control samples; the intra-day precision was estimated at 13.5, 9.1, 7.8% and the inter-day precision at 17.9, 8.4, 9.3%, The limit of quantification of the method was evaluated at 10 mug l(-1). First toxicokinetic parameters determined on dogs plasma samples after one 3,4-DAP oral administration of 1 mg kg(-1) were: C-max = 395.7 mug l(-1); T-max = 15 min; t(1/2) = 113.6 min; Clearance/F = 16.8 ml kg(-1) min(-1) and Vd/F = 2.71 kg(-1). (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:261 / 266
页数:6
相关论文
共 18 条
[1]
PRELIMINARY TRIAL OF 3,4-DIAMINOPYRIDINE IN PATIENTS WITH MULTIPLE-SCLEROSIS [J].
BEVER, CT ;
LESLIE, J ;
CAMENGA, DL ;
PANITCH, HS ;
JOHNSON, KP .
ANNALS OF NEUROLOGY, 1990, 27 (04) :421-427
[2]
Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: Results of a randomized, double-blind, placebo-controlled, crossover trial [J].
Bever, CT ;
Anderson, PA ;
Leslie, J ;
Panitch, HS ;
DhibJalbut, S ;
Khan, OA ;
Milo, R ;
Hebel, JR ;
Conway, KL ;
Katz, E ;
Johnson, KP .
NEUROLOGY, 1996, 47 (06) :1457-1462
[3]
CHAPUZET E, 1998, STP PHARM PRATIQUES, V8, P81
[4]
Chapuzet E., 1997, STP Pharma Pratiques, V7, P169
[5]
CHAPUZET E, 2000, STP PHARM PRATIQUES, V10, P21
[6]
CHAPUZET E, 2000, STP PHARM PRATIQUES, P79
[7]
FLOREY K, 1974, ANAL PROFILES DRUG S, P483
[8]
DETERMINATION OF 3,4-DIAMINOPYRIDINE IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY [J].
KAMALI, F ;
NICHOLSON, E .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1995, 13 (06) :791-794
[9]
ANALYSIS OF 3,4-DIAMINOPYRIDINE IN HUMAN-SERUM BY SOLID-PHASE EXTRACTION AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ULTRAVIOLET DETECTION [J].
LESLIE, J ;
BEVER, CT .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1989, 496 (01) :214-222
[10]
TREATMENT OF LAMBERT-EATON SYNDROME - 3,4-DIAMINOPYRIDINE AND PYRIDOSTIGMINE [J].
LUNDH, H ;
NILSSON, O ;
ROSEN, I .
NEUROLOGY, 1984, 34 (10) :1324-1330